EKF Diagnostics (LON:EKF) Announces Quarterly Earnings Results

EKF Diagnostics (LON:EKF) announced its earnings results on Tuesday. The company reported GBX 1.38 ($0.02) EPS for the quarter, Digital Look Earnings reports. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%.

EKF Diagnostics Stock Performance

EKF traded down GBX 0.40 ($0.01) during trading on Thursday, hitting GBX 21.60 ($0.28). The stock had a trading volume of 3,655,892 shares, compared to its average volume of 566,477. The firm has a market capitalization of £96.01 million, a P/E ratio of 20.10 and a beta of 0.57. The company’s 50-day moving average price is GBX 23.23 and its 200 day moving average price is GBX 25.85. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60. EKF Diagnostics has a twelve month low of GBX 18.40 ($0.24) and a twelve month high of GBX 33.80 ($0.44).

Insider Activity

In other EKF Diagnostics news, insider Gavin T. Jones acquired 50,000 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was purchased at an average price of GBX 22 ($0.28) per share, for a total transaction of £11,000 ($14,162.48). Insiders own 5.24% of the company’s stock.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.